SRPT – Sarepta Therapeutics, Inc.
Sarepta Therapeutics, Inc.SRPT
$20.12Name : Sarepta Therapeutics, Inc.
Sector : Healthcare
Industry: Biotechnology
Mark. Cap: $2,111,344,512.00
EPSttm : -7.13
Sarepta Therapeutics, Inc.
$20.11
0.70%$0.14
SRPT — Price & Forward EBITDA
Forward EBITDA (M)
Float Short %
23.02
Margin Of Safety %
Put/Call OI Ratio
0.81
EPS Next Q Diff
5.03
EPS Last/This Y
11.3
EPS This/Next Y
-1.39
Price
19.94
Target Price
22.33
Analyst Recom
2.69
Performance Q
-10.53
Upside
-649.4%
Beta
0.26
Ticker: SRPT
of 1
| Date | Symbol | Latest | P/C OI | P/C Vol | Total OI |
|---|---|---|---|---|---|
| 2026-03-02 | SRPT | 16.31 | 0.94 | 0.63 | 112088 |
| 2026-03-03 | SRPT | 15.88 | 0.94 | 1.93 | 113552 |
| 2026-03-04 | SRPT | 16.13 | 0.95 | 0.72 | 114971 |
| 2026-03-05 | SRPT | 16.23 | 0.94 | 0.60 | 115501 |
| 2026-03-06 | SRPT | 16.72 | 0.94 | 0.13 | 115488 |
| 2026-03-09 | SRPT | 17.64 | 0.90 | 0.29 | 118018 |
| 2026-03-10 | SRPT | 17.66 | 0.89 | 0.15 | 119925 |
| 2026-03-11 | SRPT | 17.58 | 0.86 | 0.57 | 122179 |
| 2026-03-12 | SRPT | 17.04 | 0.87 | 1.08 | 123274 |
| 2026-03-13 | SRPT | 17.04 | 0.87 | 1.09 | 123274 |
| 2026-03-17 | SRPT | 16.85 | 0.88 | 0.52 | 122564 |
| 2026-03-18 | SRPT | 17.17 | 0.88 | 0.47 | 123418 |
| 2026-03-19 | SRPT | 16.66 | 0.87 | 0.66 | 123924 |
| 2026-03-20 | SRPT | 16.7 | 0.86 | 0.43 | 124924 |
| 2026-03-23 | SRPT | 17.7 | 0.89 | 0.90 | 112327 |
| 2026-03-24 | SRPT | 17.62 | 0.89 | 0.42 | 117039 |
| 2026-03-25 | SRPT | 23.74 | 0.89 | 0.21 | 118132 |
| 2026-03-26 | SRPT | 21.67 | 0.81 | 0.53 | 125415 |
| 2026-03-27 | SRPT | 19.95 | 0.81 | 0.46 | 125467 |
| Date | Symbol | Latest | P/C OI | P/C Vol | Total OI |
Current Page1 of 1
of 1
| Date | Ticker | Price | Current Quarter Growth Estimate | EBIT Estimation | Average EPS Estimate Current Year |
|---|---|---|---|---|---|
| 2026-03-02 | SRPT | 16.31 | 115.0 | 345.9 | 2.38 |
| 2026-03-03 | SRPT | 15.88 | 124.6 | 343.4 | 2.38 |
| 2026-03-04 | SRPT | 16.08 | 119.4 | 344.6 | 2.38 |
| 2026-03-05 | SRPT | 16.23 | 119.4 | 345.4 | 2.38 |
| 2026-03-06 | SRPT | 16.70 | 119.4 | 346.9 | 2.38 |
| 2026-03-09 | SRPT | 17.64 | 126.8 | 767.7 | 4.33 |
| 2026-03-10 | SRPT | 17.67 | 126.8 | 767.8 | 4.33 |
| 2026-03-11 | SRPT | 17.56 | 128.8 | 767.3 | 4.33 |
| 2026-03-12 | SRPT | 17.06 | 128.8 | 764.5 | 4.33 |
| 2026-03-13 | SRPT | 16.41 | 128.8 | 760.8 | 4.23 |
| 2026-03-17 | SRPT | 16.84 | 128.8 | 763.3 | 4.38 |
| 2026-03-18 | SRPT | 17.17 | 128.8 | 765.1 | 4.38 |
| 2026-03-19 | SRPT | 16.66 | 128.8 | 762.2 | 4.38 |
| 2026-03-20 | SRPT | 16.69 | 126.7 | 762.4 | 4.17 |
| 2026-03-23 | SRPT | 17.70 | 126.7 | 768.0 | 4.17 |
| 2026-03-24 | SRPT | 17.61 | 126.7 | 767.6 | 4.17 |
| 2026-03-25 | SRPT | 23.78 | 126.7 | 801.9 | 4.17 |
| 2026-03-26 | SRPT | 21.66 | 126.7 | 790.1 | 4.17 |
| 2026-03-27 | SRPT | 19.94 | 126.7 | 780.5 | 4.17 |
| Date | Ticker | Price | Current Quarter Growth Estimate | EBIT Estimation | Average EPS Estimate Current Year |
Current Page1 of 1
of 1
| Date | Ticker | Insider Transactions | Institutional Transactions | Float Short |
|---|---|---|---|---|
| 2026-03-02 | SRPT | -0.24 | -0.58 | 22.37 |
| 2026-03-03 | SRPT | -0.24 | -0.58 | 22.37 |
| 2026-03-04 | SRPT | -0.24 | -0.58 | 22.37 |
| 2026-03-05 | SRPT | -0.24 | -0.58 | 22.32 |
| 2026-03-06 | SRPT | -0.24 | -0.58 | 22.32 |
| 2026-03-09 | SRPT | -0.24 | -0.58 | 22.32 |
| 2026-03-10 | SRPT | -0.24 | -0.58 | 22.32 |
| 2026-03-11 | SRPT | -0.24 | -0.58 | 21.36 |
| 2026-03-12 | SRPT | -0.24 | -0.58 | 21.36 |
| 2026-03-13 | SRPT | -0.24 | -0.58 | 21.36 |
| 2026-03-17 | SRPT | -0.37 | -0.58 | 21.36 |
| 2026-03-18 | SRPT | -0.37 | -0.58 | 21.36 |
| 2026-03-19 | SRPT | -0.37 | -0.58 | 21.36 |
| 2026-03-20 | SRPT | -0.37 | -0.58 | 21.36 |
| 2026-03-23 | SRPT | -0.37 | -0.65 | 21.36 |
| 2026-03-24 | SRPT | -0.37 | -0.65 | 21.36 |
| 2026-03-25 | SRPT | -0.37 | -0.65 | 23.02 |
| 2026-03-26 | SRPT | -0.37 | -0.65 | 23.02 |
| 2026-03-27 | SRPT | -0.37 | -0.65 | 23.02 |
| Date | Ticker | Insider Transactions | Institutional Transactions | Float Short |
Current Page1 of 1
Last Quarter Act. EPS
-3.93
Avg. EPS Est. Current Quarter
0.91
Avg. EPS Est. Next Quarter
1.1
Insider Transactions
-0.37
Institutional Transactions
-0.65
Beta
0.26
Average Sales Estimate Current Quarter
475
Average Sales Estimate Next Quarter
436
Fair Value
Quality Score
38
Growth Score
35
Sentiment Score
39
Actual DrawDown %
88.5
Max Drawdown 5-Year %
-92.7
Target Price
22.33
P/E
Forward P/E
16
PEG
P/S
0.95
P/B
1.84
P/Free Cash Flow
EPS
-8.44
Average EPS Est. Cur. Y
4.17
EPS Next Y. (Est.)
2.77
Target Price Estimates Raised
1
Target Price Estimates Lowered
Profit Margin
-38.34
Relative Volume
1.55
Return on Equity vs Sector %
-89.9
Return on Equity vs Industry %
-73.6
EPS 1 7Days Diff
-0.1
EPS 1 30Days Diff
1.07
EBIT Estimation
780.5
◆
SRPT
Healthcare
$19.97
Swing / Pullback
Buy the dip on strong trends
WEAK
RSI
56.1
Range 1M
56.5%
Momentum Growth
Ride accelerating trends
WEAK
EPS Yr
141.6%
EPS NY
-57.9%
52W%
15.9%
Long-Term Value
Quality companies, undervalued
WEAK
🟢 BUY
+60.7% upside
Upside
+60.7%
Quality
38
Sarepta Therapeutics, Inc.Sector: Healthcare
Industry: Biotechnology
Employees: 835
Sarepta Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, siRNA platform, gene therapy, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 for the treatment of Duchenne in patients who have a confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of Duchenne in patients who have a confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of Duchenne in patients who have a confirmed mutation of the dystrophin gene that is amenable to exon 45 skipping; and ELEVIDYS, an AAV-based gene therapy, which is contraindicated in patients with any deletion in exon 8 and/or exon 9 in the Duchenne gene. The company also develops SRP-9003, a gene therapy program for the treatment of LGMD2E; SRP-1001 to selectively target and knockdown DUX4 using RNAi in Phase 1/2a clinical trials; and SRP-1003 for reduction of expression of the DMPK gene in Phase 1/2a clinical trials. It has collaboration and license agreements with F. Hoffman-La Roche Ltd; Arrowhead Pharmaceuticals, Inc.; University of Western Australia; Nationwide Children's Hospital; Hansa Biopharma; and Duke University. The company was incorporated in 1980 and is headquartered in Cambridge, Massachusetts.
SRPT
Latest News
—
Caricamento notizie per SRPT…
stock quote shares SRPT – Sarepta Therapeutics, Inc. Stock Price stock today
news today SRPT – Sarepta Therapeutics, Inc. stock forecast ,stock prediction 2023 2024 2025
marketwatch SRPT – Sarepta Therapeutics, Inc. yahoo finance google finance
stock history SRPT – Sarepta Therapeutics, Inc. invest stock market
stock prices SRPT premarket after hours
ticker SRPT fair value insiders trading